Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial

Autor: E.M. Swisher, R.L. Coleman, M.A. Bookman, M.F. Brady, G.F. Fleming, M. Friedlander, M.J. Cunningham, K.S. Tewari, B. Edraki, K. Moxley, G.M. Mantia-Smaldone, C. Ratajczak, M.H. Dinh, D.M. Sullivan, S. McClain, S. Okubo, K.D. Steffensen, C. Aghajanian

Publikováno v: Swisher, E M, Coleman, R L, Bookman, M A, Brady, M F, Fleming, G F, Friedlander, M, Cunningham, M J, Tewari, K S, Edraki, B, Moxley, K, Mantia-Smaldone, G M, Ratajczak, C, Dinh, M H, Sullivan, D M, McClain, S, Okubo, S, Steffensen, K D & Aghajanian, C 2020, ' Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial ', Gynecologic Oncology, vol. 159, no. Suppl. 1, 37, pp. 20-21 . https://doi.org/10.1016/j.ygyno.2020.06.040

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bcffd59bfaec80a515d4f13e9b0c4f3
https://portal.findresearcher.sdu.dk/da/publications/539057a3-b974-4e71-aad8-5be200b0af3d

Anti-tumor activity of veliparib during combination phase with chemotherapy in velia study

Autor: D.M. O'Malley, M.A. Bookman, K.N. Moore, G.F. Fleming, M.F. Brady, E.M. Swisher, C. Aghajanian, K.D. Steffensen, M. Friedlander, A. Okamoto, N.M. Spirtos, M.S. Shahin, T.J. Reid, D.M. Sullivan, V. Sehgal, P.J. Ansell, M.H. Dinh, R.L. Coleman

Publikováno v: Gynecologic Oncology. 159:52-53

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a4973e92289ec22689dda192715d376
https://doi.org/10.1016/j.ygyno.2020.06.110

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer

Autor: M.A. Bookman

Publikováno v: Annals of Oncology. 21:vii211-vii217

Advanced-stage epithelial ovarian cancer is generally managed with cytoreductive surgery and chemotherapy consisting of carboplatin and paclitaxel, achieving clinical complete remission in the majority of patients. However, most tumors recur, and are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42eeb3392b714a8406029a3c14e3939f
https://doi.org/10.1093/annonc/mdq368